Vanda Pharmaceuticals Inc. Logo

Vanda Pharmaceuticals Inc.

VNDA

(2.5)
Stock Price

5,11 USD

1.89% ROA

0.46% ROE

18.96x PER

Market Cap.

223.224.160,00 USD

1.81% DER

0% Yield

1.3% NPM

Vanda Pharmaceuticals Inc. Stock Analysis

Vanda Pharmaceuticals Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vanda Pharmaceuticals Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.38x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 ROE

The stock's ROE falls within an average range (2.81%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (2.39%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

7 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (41), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

8 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Vanda Pharmaceuticals Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vanda Pharmaceuticals Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Vanda Pharmaceuticals Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vanda Pharmaceuticals Inc. Revenue
Year Revenue Growth
2004 33.980
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 4.547.744 100%
2010 35.220.000 87.09%
2011 31.270.000 -12.63%
2012 32.727.000 4.45%
2013 33.879.000 3.4%
2014 50.157.000 32.45%
2015 109.925.000 54.37%
2016 146.017.000 24.72%
2017 165.083.000 11.55%
2018 193.118.000 14.52%
2019 227.188.000 15%
2020 248.168.000 8.45%
2021 268.682.000 7.64%
2022 254.382.000 -5.62%
2023 155.260.000 -63.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vanda Pharmaceuticals Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2004 7.442.983
2005 16.890.615 55.93%
2006 52.070.776 67.56%
2007 47.234.867 -10.24%
2008 23.935.541 -97.34%
2009 13.873.961 -72.52%
2010 12.338.000 -12.45%
2011 28.996.000 57.45%
2012 45.446.000 36.2%
2013 28.190.000 -61.21%
2014 19.230.000 -46.59%
2015 29.145.000 34.02%
2016 29.156.000 0.04%
2017 38.547.000 24.36%
2018 43.594.000 11.58%
2019 48.649.000 10.39%
2020 55.577.000 12.47%
2021 75.363.000 26.25%
2022 85.770.000 12.13%
2023 66.400.000 -29.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vanda Pharmaceuticals Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 13.637.664 100%
2007 32.803.508 58.43%
2008 28.909.580 -13.47%
2009 23.724.101 -21.86%
2010 10.147.000 -133.8%
2011 11.486.000 11.66%
2012 13.882.000 17.26%
2013 24.594.000 43.56%
2014 84.644.000 70.94%
2015 84.531.000 -0.13%
2016 99.787.000 15.29%
2017 123.841.000 19.42%
2018 105.751.000 -17.11%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vanda Pharmaceuticals Inc. EBITDA
Year EBITDA Growth
2004 -9.151.897
2005 -23.862.918 61.65%
2006 -65.133.068 63.36%
2007 -79.538.134 18.11%
2008 -50.533.436 -57.4%
2009 -34.523.199 -46.38%
2010 9.691.000 456.24%
2011 -9.673.000 200.19%
2012 -26.730.000 63.81%
2013 -18.905.000 -41.39%
2014 -132.916.000 85.78%
2015 -27.213.000 -388.43%
2016 -7.638.000 -256.28%
2017 -15.153.000 49.59%
2018 23.265.000 165.13%
2019 24.315.000 4.32%
2020 30.103.000 19.23%
2021 43.643.000 31.02%
2022 7.845.000 -456.32%
2023 -22.460.000 134.93%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vanda Pharmaceuticals Inc. Gross Profit
Year Gross Profit Growth
2004 33.980
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 1.650.119 100%
2010 30.834.000 94.65%
2011 31.270.000 1.39%
2012 32.598.000 4.07%
2013 33.879.000 3.78%
2014 48.574.000 30.25%
2015 86.463.000 43.82%
2016 121.305.000 28.72%
2017 147.235.000 17.61%
2018 172.610.000 14.7%
2019 202.700.000 14.84%
2020 224.804.000 9.83%
2021 243.053.000 7.51%
2022 230.100.000 -5.63%
2023 143.008.000 -60.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vanda Pharmaceuticals Inc. Net Profit
Year Net Profit Growth
2004 -9.474.286
2005 -23.884.301 60.33%
2006 -63.511.168 62.39%
2007 -74.069.690 14.25%
2008 -51.064.241 -45.05%
2009 -35.858.846 -42.4%
2010 7.192.000 598.59%
2011 -9.802.000 173.37%
2012 -27.664.000 64.57%
2013 -20.255.000 -36.58%
2014 20.186.000 200.34%
2015 -39.865.000 150.64%
2016 -18.010.000 -121.35%
2017 -15.567.000 -15.69%
2018 25.208.000 161.75%
2019 115.553.000 78.18%
2020 23.337.000 -395.15%
2021 33.152.000 29.61%
2022 6.275.000 -428.32%
2023 548.000 -1045.07%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vanda Pharmaceuticals Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 -1 100%
2006 -4 66.67%
2007 -3 -50%
2008 -2 -100%
2009 -1 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 -1 0%
2014 1 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 2 100%
2020 0 0%
2021 1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vanda Pharmaceuticals Inc. Free Cashflow
Year Free Cashflow Growth
2004 -9.029.465
2005 -18.006.152 49.85%
2006 -52.973.674 66.01%
2007 -51.920.691 -2.03%
2008 -46.898.988 -10.71%
2009 157.336.278 129.81%
2010 -10.898.000 1543.72%
2011 -28.685.000 62.01%
2012 -46.934.000 38.88%
2013 -39.768.000 -18.02%
2014 -90.323.000 55.97%
2015 9.922.000 1010.33%
2016 -9.510.000 204.33%
2017 -3.647.000 -160.76%
2018 4.618.000 178.97%
2019 44.928.000 89.72%
2020 49.980.000 10.11%
2021 63.662.000 21.49%
2022 31.305.000 -103.36%
2023 -2.074.000 1609.4%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vanda Pharmaceuticals Inc. Operating Cashflow
Year Operating Cashflow Growth
2004 -8.614.934
2005 -17.714.174 51.37%
2006 -51.619.518 65.68%
2007 -51.641.258 0.04%
2008 -45.955.329 -12.37%
2009 169.336.278 127.14%
2010 -10.898.000 1653.83%
2011 -28.410.000 61.64%
2012 -44.917.000 36.75%
2013 -39.592.000 -13.45%
2014 -81.554.000 51.45%
2015 12.449.000 755.1%
2016 -8.103.000 253.63%
2017 -1.983.000 -308.62%
2018 29.986.000 106.61%
2019 45.947.000 34.74%
2020 51.775.000 11.26%
2021 64.214.000 19.37%
2022 31.984.000 -100.77%
2023 -2.050.000 1660.2%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vanda Pharmaceuticals Inc. Capital Expenditure
Year Capital Expenditure Growth
2004 414.531
2005 291.978 -41.97%
2006 1.354.156 78.44%
2007 279.433 -384.61%
2008 943.659 70.39%
2009 12.000.000 92.14%
2010 0 0%
2011 275.000 100%
2012 2.017.000 86.37%
2013 176.000 -1046.02%
2014 8.769.000 97.99%
2015 2.527.000 -247.01%
2016 1.407.000 -79.6%
2017 1.664.000 15.44%
2018 25.368.000 93.44%
2019 1.019.000 -2389.5%
2020 1.795.000 43.23%
2021 552.000 -225.18%
2022 679.000 18.7%
2023 24.000 -2729.17%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vanda Pharmaceuticals Inc. Equity
Year Equity Growth
2004 15.943.587
2005 30.664.807 48.01%
2006 26.756.872 -14.61%
2007 83.728.931 68.04%
2008 46.020.274 -81.94%
2009 23.030.858 -99.82%
2010 37.730.000 38.96%
2011 33.474.000 -12.71%
2012 9.905.000 -237.95%
2013 44.124.000 77.55%
2014 160.817.000 72.56%
2015 133.027.000 -20.89%
2016 131.330.000 -1.29%
2017 131.387.000 0.04%
2018 275.422.000 52.3%
2019 410.945.000 32.98%
2020 453.266.000 9.34%
2021 504.928.000 10.23%
2022 527.198.000 4.22%
2023 543.100.000 2.93%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vanda Pharmaceuticals Inc. Assets
Year Assets Growth
2004 17.752.241
2005 35.752.770 50.35%
2006 36.260.276 1.4%
2007 96.860.780 62.56%
2008 49.933.843 -93.98%
2009 225.714.081 77.88%
2010 213.101.000 -5.92%
2011 182.618.000 -16.69%
2012 135.448.000 -34.83%
2013 143.349.000 5.51%
2014 171.704.000 16.51%
2015 213.050.000 19.41%
2016 210.374.000 -1.27%
2017 205.425.000 -2.41%
2018 332.130.000 38.15%
2019 483.748.000 31.34%
2020 533.456.000 9.32%
2021 593.792.000 10.16%
2022 634.247.000 6.38%
2023 641.605.000 1.15%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vanda Pharmaceuticals Inc. Liabilities
Year Liabilities Growth
2004 1.808.654
2005 5.087.963 64.45%
2006 9.503.404 46.46%
2007 13.131.849 27.63%
2008 3.913.569 -235.55%
2009 202.683.223 98.07%
2010 175.371.000 -15.57%
2011 149.144.000 -17.59%
2012 125.543.000 -18.8%
2013 99.225.000 -26.52%
2014 10.887.000 -811.41%
2015 80.023.000 86.4%
2016 79.044.000 -1.24%
2017 74.038.000 -6.76%
2018 56.708.000 -30.56%
2019 72.803.000 22.11%
2020 80.190.000 9.21%
2021 88.864.000 9.76%
2022 107.049.000 16.99%
2023 98.505.000 -8.67%

Vanda Pharmaceuticals Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.68
Net Income per Share
0.2
Price to Earning Ratio
18.96x
Price To Sales Ratio
1.05x
POCF Ratio
8.6
PFCF Ratio
8.73
Price to Book Ratio
0.41
EV to Sales
0.22
EV Over EBITDA
30.11
EV to Operating CashFlow
1.83
EV to FreeCashFlow
1.86
Earnings Yield
0.05
FreeCashFlow Yield
0.11
Market Cap
0,22 Bil.
Enterprise Value
0,05 Bil.
Graham Number
6.59
Graham NetNet
7.19

Income Statement Metrics

Net Income per Share
0.2
Income Quality
2.2
ROE
0.02
Return On Assets
0
Return On Capital Employed
-0.02
Net Income per EBT
0.4
EBT Per Ebit
-0.45
Ebit per Revenue
-0.07
Effective Tax Rate
0.6

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.33
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.92
Operating Profit Margin
-0.07
Pretax Profit Margin
0.03
Net Profit Margin
0.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.45
Free CashFlow per Share
0.44
Capex to Operating CashFlow
-0.02
Capex to Revenue
-0
Capex to Depreciation
-0.16
Return on Invested Capital
-0
Return on Tangible Assets
0.02
Days Sales Outstanding
50.43
Days Payables Outstanding
72.44
Days of Inventory on Hand
20.89
Receivables Turnover
7.24
Payables Turnover
5.04
Inventory Turnover
17.47
Capex per Share
-0.01

Balance Sheet

Cash per Share
8,52
Book Value per Share
9,44
Tangible Book Value per Share
9.14
Shareholders Equity per Share
9.44
Interest Debt per Share
0.06
Debt to Equity
0.02
Debt to Assets
0.02
Net Debt to EBITDA
-111.35
Current Ratio
6.32
Tangible Asset Value
0,53 Bil.
Net Current Asset Value
0,44 Bil.
Invested Capital
0.02
Working Capital
0,45 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,03 Bil.
Average Payables
0,00 Bil.
Average Inventory
1043000
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vanda Pharmaceuticals Inc. Dividends
Year Dividends Growth

Vanda Pharmaceuticals Inc. Profile

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

CEO
Dr. Mihael H. Polymeropoulos M
Employee
203
Address
2200 Pennsylvania Avenue NW
Washington, 20037

Vanda Pharmaceuticals Inc. Executives & BODs

Vanda Pharmaceuticals Inc. Executives & BODs
# Name Age
1 Mr. Scott L. Howell
Chief People Officer
70
2 Mr. Kevin Patrick Moran
Senior Vice President, Chief Financial Officer & Treasurer
70
3 Dr. Mihael H. Polymeropoulos M.D.
Founder, President, Chief Executive Officer & Chairman of The Board
70
4 Mr. Timothy Williams
Senior Vice President, General Counsel & Secretary
70
5 Ms. Elizabeth Van Every
Head of Corporate Affairs
70
6 Mr. Gunther Birznieks
Senior Vice President of Business Development
70
7 Mr. Joakim Wijkstrom
Senior Vice President & Chief Marketing Officer
70

Vanda Pharmaceuticals Inc. Competitors